How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

779 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain

of the first visit and during the study Previous ineffective use of lidocaine patches Morbid obesity Moderate or severe depression An open skin lesion within the painful area where patches will be applied Patients with active or resolved back pain litigation or receiving disability payments due to chronic low back pain Pregnant or breastfeeding females Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study (...) Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain Study of the Efficacy and Safety of Bupivacaine TTS Patch in Patients With Chronic Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2010 Clinical Trials

142. Contribution of a heating element to topical anesthesia patch efficacy prior to vascular access: results from two randomized, double-blind studies. (PubMed)

Contribution of a heating element to topical anesthesia patch efficacy prior to vascular access: results from two randomized, double-blind studies. Pain associated with superficial procedures, including intravenous (IV) access procedures, should be prevented when possible, especially in children.To evaluate a topical local anesthetic patch containing lidocaine 70 mg/tetracaine 70 mg with a heating element designed to warm the skin and facilitate rapid delivery of local anesthetics into the skin (...) . The pilot study was designed to provide data to inform the design of the definitive study to evaluate the impact of controlled heat on the efficacy of the lidocaine/tetracaine patch (patch) when applied before IV cannulation.Subjects in the pilot study were randomized to eight groups that varied by heated vs. unheated patch, 20 vs. 30 minute application, and 16 vs. 18 G catheter. Subjects in the definitive study were randomized in a double-blind manner to receive either the heated or unheated patch, 20

2010 Journal of pain and symptom management

143. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. (PubMed)

Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. We compared the lidocaine/tetracaine patch [Synera (USA), Rapydan (Europe)], a novel heat-aided patch using a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg, with a eutectic mixture of lidocaine 25 mg ml(-1) and prilocaine 25 mg ml(-1) (EMLA Cream). The agents were administered at different time periods for local topical anaesthesia before (...) a vascular access procedure.In this double-blind, paired study, 82 adult volunteers were randomized to receive the lidocaine/tetracaine patch on one anticubital surface and lidocaine/prilocaine cream on the other concurrently for 10, 20, 30, or 60 min before a vascular access procedure. Subjects rated pain intensity using a 100 mm visual analogue scale (VAS). Skin reactions and adverse events were also evaluated.Median VAS scores were significantly lower for the lidocaine/tetracaine patch than

Full Text available with Trip Pro

2009 British Journal of Anaesthesia

144. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. (PubMed)

A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Myofascial pain syndrome (MPS), a regional pain condition caused by trigger points in muscle or muscle fascia, produces muscle pain, tenderness, and disability. The gold standard of treatment for MPS-infiltration of trigger points with anesthetic-may provoke discomfort (...) to the patients and require medical intervention.This study was designed to compare the effects of a topical lidocaine patch, a placebo patch, and injection of anesthetic (infiltration) for the symptoms of MPS in terms of pain, disability, and local tissue hypersensitivity, and to determine the acceptability of the lidocaine patch to the patients.Patients were randomly allocated to receive 1 of 3 treatments: a lidocaine patch applied to the trigger point for 4 days (replacement every 12 hours; total daily

2009 Clinical therapeutics

145. Quick guide: National clinical guideline on opioid treatment of chronic non-malignant pain

patches and capsaicin patches. In the Danish Health Authority’s National Recommendations List for treatment of patients with neuropathic pain conditions the evidence for SNRIs and lidocaine patches has been demonstrated, and the conclusion is that duloxetine can be used in patients with peripheral neuropathic pain. Venlafaxine can be used in the same group of patients if duloxetine has no effect. Lidocaine patches can be used in specific cases in patients with neuropathic pain. Both recommendation (...) examined in this guideline, but it is evident from the Danish Health Authority’s National Recommendations List for treatment of patients with nociceptive pain that there are no studies that shed light on the long-term effect ( > 6 weeks) of paracetamol, and there have been no studies comparing the effect of opioids with the effect of paracetamol. Other pharmacological treatment options that have not been examined in this guideline are serotonin and norepinephrine reuptake inhibitors (SNRIs), lidocaine

2019 Danish National Clinical Guidelines

146. Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers

Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00889642

2009 Clinical Trials

147. Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee

Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine (...) Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% With Celecoxib 200 mg in Patients With Pain From Osteoarthritis of the Knee Study Start Date : June 2004 Actual Primary Completion Date : November 2004 Actual Study Completion Date : November 2004 Resource links provided by the National Library

2009 Clinical Trials

148. Topical Lidocaine Patch in Low Back Pain

Topical Lidocaine Patch in Low Back Pain Topical Lidocaine Patch in Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Topical Lidocaine Patch in Low Back Pain The safety and scientific validity (...) ) Primary Purpose: Treatment Official Title: Open-Label Study Assessing the Efficacy of Topical Lidocaine Patch in Treatment of Low Back Pain Study Start Date : March 2002 Actual Primary Completion Date : October 2002 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Lidoderm® Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h

2009 Clinical Trials

149. Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee

Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00904462 Recruitment Status : Completed First Posted : May 19, 2009 Last Update Posted : February 10, 2010

2009 Clinical Trials

150. Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain

Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine (...) Pharmaceuticals Information provided by: Endo Pharmaceuticals Study Details Study Description Go to Brief Summary: Patients who had axial lower back pain (LBP) with or without radiation present for at least 3 months and had daily moderate to severe LBP as the primary source of pain participated in a Phase IV clinical trial to assess the efficacy of lidocaine patch 5% compared to celecoxib 200 mg in treating chronic axial LBP with and without radiation. Condition or disease Intervention/treatment Phase Chronic

2009 Clinical Trials

151. A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain

A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. A Study Comparing The Efficacy And Safety Of Lidocaine 5% Patch With Placebo In Patients With Chronic Axial Low Back Pain The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00904111 Recruitment Status : Completed First

2009 Clinical Trials

152. Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidoderm® (...) (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00903851 Recruitment Status : Completed First Posted : May 19, 2009 Last Update Posted : February 15, 2010 Sponsor: Endo Pharmaceuticals Information provided by: Endo Pharmaceuticals Study Details

2009 Clinical Trials

153. Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. (PubMed)

Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Reduced postoperative pain is one of the many factors that have driven the growing emphasis on the role of laparoscopic surgery for surgical management. Several studies have documented the advantages of the laparoscopic repair of ventral hernias compared to the open ventral herniorraphy. However, the laparoscopic approach may be associated with more postoperative pain initially (...) . In this preliminary study, we present data from our early experience with the use of a lidocaine patch for pain control in the immediate postoperative period following laparoscopic ventral hernia repair (LVH).Thirty consecutive patients underwent laparoscopic ventral herniorraphy (LVH) and were selected randomly and placed into one of two groups. In one group, we placed a lidocaine patch (LP) (Lidoderm, Endo Pharmaceuticals, Inc., Chadds Ford, PA) on the anterior abdominal wall corresponding to the placement site

Full Text available with Trip Pro

2009 International journal of surgery (London, England)

154. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). (PubMed)

Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Current therapies often have limited efficacy and untenable side effects when used to treat persistent incisional pain following cancer-related surgery. Lidocaine patches reduce neuropathic pain from herpes zoster but their benefits for persistent cancer-related postsurgical incisional pain remain unclear.Multicenter, double-blind, randomized (...) , two-period crossover trial.Twenty-eight cancer patients with postsurgical incisional pain were randomly assigned to receive either lidocaine patches followed by placebo patches or the reverse. Each study period lasted 4 weeks. Patches were applied daily upon waking and left in place for a maximum of 18 h. The primary outcome measure, an 11-point pain intensity rating scale, was administered weekly. Secondary outcomes were administered weekly (Brief Pain Inventory-Short Form(BPI-SF), Subject Global

Full Text available with Trip Pro

2009 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

155. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. (PubMed)

Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. In a prospective, double-blind, placebo-controlled study, patients undergoing radical retropubic prostatectomy under general anesthesia were randomly assigned to receive a lidocaine patch or placebo applied on each side of the wound at the end of surgery. Data were collected for 24 h after surgery. Seventy patients completed the study (36 lidocaine group, 34 placebo group). Demographics and postoperative (...) morphine consumption were not different between the groups. However, the lidocaine patch group reported significantly less pain on coughing (19%-33% reduction) over all time periods (treatment vs placebo P < 0.0001, time x treatment P = 0.3056) and at rest (17%-32% reduction) for up to 6 h (treatment vs placebo P = 0.0003, time x treatment P = 0.0130).

Full Text available with Trip Pro

2009 Anesthesia and analgesia

156. Neuropathic pain

was 6.8. Tramadol The IASP Guidelines, based on the (see also ), made a weak GRADE recommendation for second-line use based on positive trials and moderate quality of evidence, but potential safety concerns and an increase in deaths associated with its use have been reported. NNT/NNH were 4.7/12.6. The on tramadol for neuropathic pain in adults used a more stringent standard of ≥ 50% pain relief and fewer studies compared to the 2015 Finnerup study, but found a similar NNT of 4.4. Lidocaine (...) (lignocaine) patches The IASP Guidelines, based on the (see also ), made a weak GRADE recommendation for second-line use for peripheral neuropathic pain use based on poor quality of evidence, but high values and preferences, and excellent balance between desirable and undesirable side effects. NNT/NNH were not available. While the lack of high quality studies resulted in no pooling of data and meta-analysis was not performed, individual studies indicated some improvement compared to placebo

2019 National Prescribing Service Limited (Australia)

157. Diagnosis and management of gonorrhoea and syphilis

days (range 9-90) Secondary • Widespread mucocutaneous rash and generalized lymphadenopathy • Mucous patches (buccal, lingual and genital) and highly infectious condylomata lata a?ecting warm, moist areas (mostly the perineum and anus) • Hepatitis; glomerulonephritis; splenomegaly; neurological complications (meningitis, hearing loss, tinnitus); uveitis, optic neuropathy, keratitis Three months after infection 4–10 weeks after the appearance of the initial chancre Latent • Asymptomatic in 75

2019 Belgian Health Care Knowledge Centre

158. Triamcinolone

of localized alopecia areata. A randomized trial. Dermatology OPD, PNS Shifa Hospital, Karachi, from January to June 2013. Patients aged 18 - 50 years with localized alopecia areata were included in the study. Exclusion criteria were more than three patches and those on already steroid or immunosuppressive therapy. Patients were randomly allocated in two treatment groups: Group A received intralesional triamcinolone acetonide (10 mg/ml) and Group B received 2015 12. Five Year Outcomes of Ranibizumab (...) and tolerance of intraarticular injection (IAI) of triamcinolone hexacetonide (TH) for the treatment of osteoarthritis (OA) of hand interphalangeal (IP) joints. Sixty patients who underwent IAI at the most symptomatic IP joint were randomly assigned to receive TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%, or just LD (n = 30). The injected joint was immobilized with a splint for 48 h in both groups. Patients were assessed at baseline and at 1, 4, 8, and 12 weeks by a blinded observer 2015 14

2018 Trip Latest and Greatest

159. Amiodarone

evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines 2018 5. In Patients With Cardiac Arrest, Does Amiodarone or Lidocaine Increase Meaningful Survival? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page. 2017 6. Amiodarone -related thyroid dysfunction. Nowadays, amiodarone is the most commonly used antidysrhythmic drug in clinical practice (...) cases may appear similar to lobar CT Extensive bilateral alveolar and s Ground-glass opacities VII. Diagnosis Clinical diagnosis only (no lab or imaging study is diagnostic) s 2018 10. Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness | CADTH.ca Find the information you need Amiodarone versus Lidocaine for Arrhythmias: Comparative Clinical Effectiveness Amiodarone versus Lidocaine

2018 Trip Latest and Greatest

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>